Our findings therefore establish KPNA4 as a molecular signature of ALS and FTD and suggest a gain-of- KPNA4 function as a potential therapeutic target that could sustain nuclear TDP-43 essential for cellular homeostasis and neuronal function affected in TDP-43 proteinopathies. Here, TARDBP is linked to frontotemporal dementia.